Search details
1.
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
JCO Precis Oncol
; 8: e2300527, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38603652
2.
Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 8: e2300513, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38354330
3.
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
J Clin Oncol
; : JCO2302078, 2024 May 15.
Article
in English
| MEDLINE | ID: mdl-38748939
4.
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.
JCO Precis Oncol
; 7: e2200505, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36753688
5.
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 7: e2300041, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37315265
6.
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
J Clin Oncol
; 41(33): 5140-5150, 2023 Nov 20.
Article
in English
| MEDLINE | ID: mdl-37561967
7.
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.
JCO Precis Oncol
; 7: e2200609, 2023 04.
Article
in English
| MEDLINE | ID: mdl-37027810
8.
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol
; 7: e2300385, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-38096472
9.
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
JCO Precis Oncol
; 7: e2300279, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-38039429
10.
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.
JCO Precis Oncol
; 6: e2200306, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-36315917
11.
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
JCO Precis Oncol
; 6: e2200191, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36409971
Results
1 -
11
de 11
1
Next >
>>